Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chloe Kent

Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.

Latest From Chloe Kent

AAM Calls For FTC Scrutiny Of Pharmacy Benefit Manager Practices

Pharmacy benefit managers often fail to encourage the use of generic and biosimilar medications and in fact undermine patient access to these more affordable drugs, the Association for Accessible Medicines has told the US Federal Trade Commission.

Generic Drugs Biosimilars

Celltrion Juggles Biosimilar Market Share As It Shifts To Direct Marketing

Celltrion Healthcare was ultimately able to increase its revenue by 16.7%, with stronger growth expected in H2.

Sales & Earnings Biosimilars

How Can Pharma Seek To Discuss Gender Diversity?

As gender-neutral language becomes more widely used throughout the business community, the pharmaceutical industry must confront how it approaches the matter of gendered language in healthcare communications.

Diversity & Inclusion Market Intelligence

Return To Growth In Biosimilars A Priority For Biogen

Biogen’s biosimilars business took a hit in Q1 following pricing pressures and negative currency fluctuations, with the company now prioritizing the rebuilding of the segment.

Sales & Earnings Business Strategies

ANI ‘On The Cusp Of A Transformation’ Following Cortrophin Launch

ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.

Sales & Earnings Launches

Inflation Impact Must Be Considered During Generics Pricing, Says Canadian Study

Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.

Generic Drugs Pricing Strategies
See All
UsernamePublicRestriction

Register